Treatment of chronic wounds represents a challenge for both the patient and modern healthcare systemsHow it works
To produce a durable closure for hard-to-heal wounds.
Treatment is non-invasive and requires minimal staff supervision.
Healing of chronic wounds significantly decreases the financial burden of modern health care.
The underlying mechanism of action can be applied to different pathological conditions.
*The COMS® One therapy system is not cleared in the US.
We are a young company founded and based in Zurich, Switzerland since 2016. The Piomic family consists of biologists, engineers, entrepreneurs, designers, seniors and a broad group of supporters. Staffed with experts from different backgrounds and a common goal: By developing a therapy which is safe and effective, we want to set a better future for patients in need.More about us
In order to maximize our global impact, we are looking for investors who share our vision and wish to shape the future of wound care with us.Information for investors
01 Dec 2022
Piomic Medical receives unconditional IDE approval from the FDA for MAVERICKS, the pivotal study for the COMS® One Therapy System in patients with refractory diabetic foot ulcers.Read more
05 Aug 2022
Highly experienced expert in advanced wound care appointed Chairman of the Board of Directors.Read more
29 Jul 2022
Piomic Medical closes oversubscribed financing round to bring COMS® therapy into US patients’ homesRead more